Nature Search

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

In a case series of eight pediatric patients with systemic lupus erythematosus, dermatomyositis or systemic sclerosis, autologous anti-CD19 CAR T cell therapy was feasible, safe and effective in reducing disease activity.

Marco Becilli
Markus Metzler
Franco Locatelli
Research05 Feb 2026
Nature Medicine

P: 1-13
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

In the phase 1/2 CASTLE basket trial, autologous CD19 CAR-T cell therapy in patients with treatment-refractory systemic lupus erythematosus, systemic sclerosis or idiopathic inflammatory myopathy was safe, with improved disease activity and patient-reported global health in most patients.

Fabian Müller
Melanie Hagen
Georg Schett
ResearchOpen Access07 Jan 2026
Nature Medicine

P: 1-10
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Andreas Mackensen
Fabian Müller
Georg Schett
Amendments and Corrections03 Nov 2022
Nature Medicine

Volume: 29, P: 2956
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Results from a study of five patients with refractory systemic lupus erythematosus, who were treated with anti-CD19 CAR T cell therapy under a compassionate-use program, demonstrate remission of SLE disease with follow-up of up to 17 months.

Andreas Mackensen
Fabian Müller
Georg Schett
Research15 Sept 2022
Nature Medicine

Volume: 28, P: 2124-2132
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

Zeiser and colleagues show that CAR T cell therapy results in upregulation of the TGFβ-activated kinase-1 (TAK1)–NF-κB–p38 MAPK pathway in microglia, causing neurocognitive defects, and find that TAK1 inhibition can reduce immune effector cell-associated neurotoxicity syndrome.

Janaki Manoja Vinnakota
Francesca Biavasco
Robert Zeiser
Research13 May 2024
Nature Cancer

Volume: 5, P: 1227-1249
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

In a patient with treatment-refractory idiopathic inflammatory myositis, reinfusion of CD19 CAR T cells following disease relapse led to the development of T cells targeting the CD19 CAR and no clinical improvement, with drug-free remission induced again after treatment with BCMA CAR T cells.

Fabian Müller
Andreas Wirsching
Ricardo Grieshaber-Bouyer
ResearchOpen Access17 Apr 2025
Nature Medicine

Volume: 31, P: 1793-1797
Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients

Franziska Karl
Andrej Stoll
Dimitrios Mougiakakos
Research23 Jul 2020
Leukemia

Volume: 35, P: 910-915
The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome

Silja Richter
Martin Böttcher
Dimitrios Mougiakakos
ResearchOpen Access06 Jul 2022
Scientific Reports

Volume: 12, P: 1-15
High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann
Astghik Voskanyan
J. Mayer
ResearchOpen Access07 May 2020
Leukemia

Volume: 34, P: 2074-2086
Bacterial nanocellulose stimulates mesenchymal stem cell expansion and formation of stable collagen-I networks as a novel biomaterial in tissue engineering

Martin Vielreicher
Dana Kralisch
Oliver Friedrich
ResearchOpen Access20 Jun 2018
Scientific Reports

Volume: 8, P: 1-14
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann
Astghik Voskanyan
J. Mayer
Amendments and Corrections10 Sept 2020
Leukemia

Volume: 34, P: 2823

Search

Filter By:

Search

Quick links